101 related articles for article (PubMed ID: 25164596)
1. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions.
Areia M; Dinis-Ribeiro M; Rocha Gonçalves F
Helicobacter; 2014 Dec; 19(6):425-36. PubMed ID: 25164596
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia.
Dinis-Ribeiro M; da Costa-Pereira A; Lopes C; Moreira-Dias L
J Gastroenterol Hepatol; 2007 Oct; 22(10):1594-604. PubMed ID: 17845687
[TBL] [Abstract][Full Text] [Related]
3. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer.
Yeh JM; Hur C; Kuntz KM; Ezzati M; Goldie SJ
Cancer; 2010 Jun; 116(12):2941-53. PubMed ID: 20564399
[TBL] [Abstract][Full Text] [Related]
5. Determining the cost-effectiveness of endoscopic surveillance for gastric cancer in patients with precancerous lesions.
Wu JT; Zhou J; Naidoo N; Yang WY; Lin XC; Wang P; Ding JQ; Wu CB; Zhou HJ
Asia Pac J Clin Oncol; 2016 Dec; 12(4):359-368. PubMed ID: 27452189
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of endoscopic surveillance for gastric intestinal metaplasia.
Hassan C; Zullo A; Di Giulio E; Annibale B; Lahner E; De Francesco V; Ierardi E
Helicobacter; 2010 Jun; 15(3):221-6. PubMed ID: 20557364
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus.
Gordon LG; Mayne GC; Hirst NG; Bright T; Whiteman DC; ; Watson DI
Gastrointest Endosc; 2014 Feb; 79(2):242-56.e6. PubMed ID: 24079411
[TBL] [Abstract][Full Text] [Related]
8. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
Provenzale D; Schmitt C; Wong JB
Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
[TBL] [Abstract][Full Text] [Related]
9. [Recommended endoscopic surveillance of patients with Barrett's esophagus (BE) is a cost-effective strategy?].
Remes-Troche JM; Ramírez-Arias JF; Gómez-Escudero O; Valdovinos-Andraca F; Vargas-Vorácková F
Rev Gastroenterol Mex; 2006; 71(1):46-54. PubMed ID: 17061478
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk.
Zhou HJ; Dan YY; Naidoo N; Li SC; Yeoh KG
PLoS One; 2013; 8(12):e83959. PubMed ID: 24386314
[TBL] [Abstract][Full Text] [Related]
11. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies.
Areia M; Carvalho R; Cadime AT; Rocha Gonçalves F; Dinis-Ribeiro M
Helicobacter; 2013 Oct; 18(5):325-37. PubMed ID: 23566268
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the endoscopic versus microscopic approach for pituitary adenoma resection.
Rudmik L; Starreveld YP; Vandergrift WA; Banglawala SM; Soler ZM
Laryngoscope; 2015 Jan; 125(1):16-24. PubMed ID: 24938934
[TBL] [Abstract][Full Text] [Related]
13. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
[TBL] [Abstract][Full Text] [Related]
14. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands.
de Vries AC; van Grieken NC; Looman CW; Casparie MK; de Vries E; Meijer GA; Kuipers EJ
Gastroenterology; 2008 Apr; 134(4):945-52. PubMed ID: 18395075
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk.
Areia M; Spaander MC; Kuipers EJ; Dinis-Ribeiro M
United European Gastroenterol J; 2018 Mar; 6(2):192-202. PubMed ID: 29511549
[TBL] [Abstract][Full Text] [Related]
17. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
[TBL] [Abstract][Full Text] [Related]
18. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer.
den Hoed CM; Holster IL; Capelle LG; de Vries AC; den Hartog B; Ter Borg F; Biermann K; Kuipers EJ
Endoscopy; 2013; 45(4):249-56. PubMed ID: 23533073
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life and utilities in gastric premalignant conditions and malignant lesions: a multicentre study in a high prevalence country.
Areia M; Alves S; Brito D; Cadime AT; Carvalho R; Saraiva S; Ferreira S; Moleiro J; Pereira AD; Carrasquinho J; Lopes L; Ramada J; Marcos-Pinto R; Pedroto I; Contente L; Eliseu L; Vieira AM; Sampaio M; Sousa HT; Almeida N; Gregório C; Portela F; Sofia C; Braga V; Baginha E; Bana e Costa T; Chagas C; Mendes LL; Magalhães-Costa P; Matos L; Gonçalves FR; Dinis-Ribeiro M
J Gastrointestin Liver Dis; 2014 Dec; 23(4):371-8. PubMed ID: 25531994
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
